La Fondation Bill & Melinda Gates annonce un soutien supplémentaire pour promouvoir la R&D locale. Appels à propositions

BRUXELLES25 octobre 2022 /PRNewswire/ — La Fondation Bill & Melinda Gates a annoncé aujourd’hui une série d’initiatives et un appel à propositions en vue de faire progresser l’innovation locale qui soutient les travaux de scientifiques et de chercheurs dans les économies en développement. L’annonce a été faite lors de la réunion annuelle de Grand Challenges plus tôt aujourd’hui.

La réunion de cette année se concentre sur les enseignements tirés de la pandémie de COVID-19, qui a mis en évidence la nécessité de plateformes de R&D à fort impact, de partenariats et de politiques qui comblent efficacement le fossé existant entre l’innovation et l’accès équitable. La réunion rapproche des chercheurs du monde entier pour partager leurs travaux, en apprendre davantage sur les avancées de pointe dans le domaine des soins de santé et permettre une collaboration avec d’autres chercheurs.

« L’équité en santé ne devrait pas uniquement être un énoncé de la raison pour laquelle nous faisons ce travail. Elle devrait guider la façon dont nous le réalisons », a déclaré Kedest Tesfagiorgis, directeur adjoint des Partenariats mondiaux et des grands défis à la Fondation Bill & Melinda Gates. « Lorsque nous soutenons l’innovation locale, nous maximisons l’impact en mettant en lumière différents types de connaissances et de perspectives. »

Dans le cadre de l’Appel mondial à l’action de Grand Challenges, une initiative sur 10 ans annoncée lors de la réunion de l’année dernière pour aider à s’assurer que les scientifiques et les institutions des pays à revenu faible et intermédiaire (PRFI) jouent un rôle central dans l’élaboration du programme mondial de R&D, deux nouvelles initiatives Grand Challenges ont été annoncée par la fondation :

  • La surveillance génomique des agents pathogènes et l’immunologie en Asie Il s’agit d’une invitation à soumission par les chercheurs en Asie du Sud et du Sud-Est pour concevoir et piloter un programme de surveillance génomique ou de développer des capacités en immunologie et séquençage immunitaire du SRAS-CoV-2 afin d’éclairer la réponse épidémique. Un montant allant jusqu’à 300 000 $ par année pour une période maximale de deux ans seront disponibles pour chaque projet, avec un financement supplémentaire potentiel pour les projets qui mettent l’accent sur la recherche d’anticorps monoclonaux.
  • Le renforcement des capacités de modélisation des données pour l’égalité des sexes  Il s’agit d’un appel à propositions lancé aux chercheurs de pays à revenu faible ou intermédiaire pour des projets visant à éliminer les disparités et les lacunes affectant les femmes et les filles dans le domaine de la santé. Cette initiative est axée sur des approches novatrices de modélisation pour faire progresser l’égalité des sexes. Chaque projet recevra jusqu’à 500 000 $ sur une période d’un à trois ans.

« Les sociétés mesurent ce qu’elles valorisent, et pour une grande partie de l’histoire, la société n’a pas valorisé les femmes. Cela signifie que nous essayons de relever des défis mondiaux en matière de santé et de développement sans disposer de toutes les informations nécessaires », a déclaré Anita Zaidi, présidente du département de l’Égalité des sexes à la Fondation Bill & Melinda Gates. « Il est grand temps de placer les femmes et les filles au centre de la modélisation des données qui guide nos solutions. »

En partenariat avec l’Initiative Chan Zuckerberg (CZI), la fondation accordera également des subventions aux chercheurs qui étudient et détectent les agents pathogènes émergents dans les PRFI. Les chercheurs recevront jusqu’à 200 000 $ chacun, pour une période maximale de deux ans, ainsi que le soutien opérationnel et une formation technique du Biohub Chan Zuckerberg  (CZ Biohub). Cet engagement de financement s’appuie sur un partenariat de 2018 entre la fondation, CZI et le CZ Biohub, qui se concentre sur le renforcement des capacités métagénomiques dans les PRFI par le biais d’une Initiative mondiale Grand Challenges.

La réunion annuelle de Grand Challenges 2022 à Bruxelles est organisée par Global Grand Challenges et la Commission européenne, et est coparrainée par Grands Défis Canada, USAID, Wellcome et la Fondation Bill & Melinda Gates.

L’événement de deux jours réunit des dizaines de leaders du paysage mondial de l’innovation en santé, ainsi que des dirigeants de la Fondation Gates, notamment Bill Gates (coprésident et administrateur), Anita Zaidi et Trevor Mundel (Président, Division de la santé mondiale). Les séances plénières seront publiées peu après la réunion sur le site grandchallenges.org/annual-meeting.

À propos de Grand Challenges

La Fondation Bill & Melinda Gates reconnaît que la résolution des défis les plus urgents en matière de santé et de développement mondiaux nécessite que davantage des esprits les plus brillants du monde y travaillent. La série d’initiatives Grand Challenges cherche à mobiliser des innovateurs du monde entier pour aider à résoudre ces défis. Les initiatives Grand Challenges sont unies par leur volonté de favoriser l’innovation, d’orienter la recherche là où elle aura le plus grand impact et d’aider ceux qui en ont le plus besoin. Pour en savoir plus, visitez le site grandchallenges.org.

À propos de la Fondation Bill & Melinda Gates

Guidée par la conviction que chaque vie a la même valeur, la Fondation Bill & Melinda Gates s’efforce d’aider toutes les personnes à mener une vie saine et productive. Dans les pays en développement, elle vise à améliorer la santé des populations et à leur donner la possibilité de ne plus souffrir de la faim et de l’extrême pauvreté. Aux États-Unis, elle vise à faire en sorte que toutes les personnes, en particulier celles qui ont le moins de ressources, aient accès aux opportunités dont elles ont besoin pour réussir à l’école et dans la vie. Basée à Seattle, Washington, la fondation est dirigée par son PDG Mark Suzman, sous la direction des coprésidents Bill Gates et Melinda French Gates et du Conseil d’administration.

Contact pour les médias : media@gatesfoundation.org

IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on TwitterFacebookLinkedInInstagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

 IAVI to Accelerate Promising Investigational Sudan Ebolavirus Vaccine Development for Potential Outbreak Research and Response

Merck will provide the investigational vaccine based on a proven platform technology

NEW YORK, NY / ACCESSWIRE / October 25, 2022 / IAVI, a nonprofit scientific research organization, and Merck, known as MSD outside the United States and Canada, have entered into an agreement that could enable IAVI to accelerate the entry of a promising Sudan ebolavirus (SUDV) vaccine candidate that IAVI is developing into clinical evaluation in response to the rapidly spreading outbreak of SUDV disease in Uganda.

Merck plans to produce and provide vials of candidate vaccine from existing investigational drug substance to IAVI to supplement IAVI’s ongoing SUDV vaccine development program. The investigational vaccine being produced is based on the same vesicular stomatitis virus (VSV) viral vector platform that is used in ERVEBO®, Merck’s highly efficacious, single-dose Zaire ebolavirus (EBOV) vaccine that has achieved regulatory approval by the U.S. FDA, the European Medicines Agency (EMA) and a number of regulatory authorities in Africa.

IAVI and Merck have been in discussions with the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders regarding the potential production and supply of doses of investigational SUDV vaccine to help support the WHO’s efforts to conduct a clinical trial of vaccine candidates in Uganda, in partnership with the Government of Uganda.

Mark Feinberg, M.D., Ph.D., president and CEO of IAVI, said, “We are grateful to Merck for supplying the vaccine material, and we look forward to the opportunity to demonstrate vaccine effectiveness and safety so that we are prepared for future outbreaks of SUDV, as well as the SUDV outbreak in Uganda should it not be promptly contained by public health measures alone. Outbreak response is more effective at containing disease spread when countermeasures work quickly, and we are hopeful that this one-dose vaccine, which is likely to generate a rapid immune response, will be a critical part of Sudan virus containment efforts in the future.”

“We are proud to work together with IAVI in support of the World Health Organization’s response to address the Sudan Ebola outbreak in Uganda,” said Beth-Ann Coller, executive director, Global Clinical Development Vaccines, Merck Research Laboratories. “We are moving with urgency to prepare these vials and donate them to IAVI as quickly as possible to help support the efforts of the WHO and the people of Uganda as they grapple with this outbreak.”

Production schedules and quantities are still being defined. Based on the quantities of available bulk drug substance and current plans, Merck hopes to be able to deliver approximately 55,000 doses by the end of the year. IAVI is actively working to accelerate the manufacture of additional doses of IAVI’s VSV-SUDV vaccine should they be needed. The number of doses provided by Merck should be sufficient for conducting Phase I and efficacy studies as well as for public health response if the outbreak in Uganda continues or spreads and should the vaccine be shown to be safe and efficacious.

IAVI will act as developer and regulatory sponsor and will be responsible for all aspects of future development of the vaccine candidate.

No SUDV vaccines have been approved to date, and existing EBOV vaccines and treatments are not effective against SUDV. In the midst of the ongoing SUDV disease outbreak, ensuring that all promising vaccine candidates are evaluated for safety and efficacy could enable vaccine stockpiles to be established for use in future outbreaks.

Vesicular stomatitis virus is the vector that underpins ERVEBO® as well as IAVI’s portfolio of emerging infectious disease vaccine candidates. These include the SUDV vaccine candidate supported by the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services; a Lassa fever virus vaccine candidate currently in a Phase I trial and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European & Developing Countries Clinical Trials Partnership (EDCTP); a Marburg virus vaccine candidate supported by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD) and BARDA; and an intranasal SARS-CoV-2 vaccine candidate supported by the Japan Ministry of Finance. VSV is a harmless animal virus; in the vaccine platform, it is engineered to encode a surface protein from a target pathogen – in this case, SUDV – that stimulates an immune response.

IAVI holds a nonexclusive license to the VSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.

About IAVI

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

Funders who have made the development of IAVI’s VSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K Department for International Development; the U.S. National Institutes of Health (NIH); and through the generous support of the American people from the United States Agency for International Development (USAID).

Follow IAVI on TwitterFacebookLinkedInInstagram, and YouTube, and subscribe to our news updates.

IAVI Media Contact

Karie Youngdahl
Head, Global Communications
kyoungdahl@iavi.org
+1 332-282-2890

SOURCE: IAVI

Ethiopia Calls for Reformed, Efficient & Viable UN Fit for Purpose in 21st Century

Ethiopia called for an inclusive, fair, effective and representative multilateralism to better respond to humanity’s most pressing challenges, building on the opportunities to amplify the pillars of the UN charter while celebrating UN Day.

On October 24, the United Nations celebrates the anniversary of the UN Charter’s entry into force in 1945.

Ministry of Foreign Affairs said in a press statement issued in connection with the celebration of UN Day, as a founding member of the United Nations, Ethiopia has remained committed to the principles of the United Nations Charter.

Ethiopia, while celebrating multilateralism anchored on the UN Charter and its cardinal principles, calls for a reformed, efficient and viable United Nations fit for purpose in the 21st century, the statement said.

As a firm believer in multilateralism, Ethiopia continues to be committed to global common aspirations for development, it said.

According to the statement, Ethiopia is proud and privileged to have hosted the United Nations Economic Commission for Africa  (UNECA) for over 60 years.

“Demonstrating our contribution to global peace and collective security, Ethiopian men and women have continued to play a robust role from the early days of UN peacekeeping missions in the 1950s.’

 

Source: Ethiopia News Agency

The Midterm Review of the Implementation of the Sendai Framework for Disaster Risk Reduction 2015-2030 – Ethiopian Voluntary National Report, September 2022

HIGHLIGHTS AND INTRODUCTION

The Ethiopian Disaster Risk Management Commission (EDRMC) was established in 2015 by the Council of Ministers through Regulation No. 363/2015 and was relocated in late 2021 to report directly to the Prime Minister (fig 1). It is responsible for coordinating and supporting the implementation of the 2013 DRM policy and strategy throughout its organizational structures, at all administrative levels and across all relevant sectors.

Ethiopia showed its commitment to the Sendai framework for disaster risk reduction and its implementation modality in Africa–the program of action (POA)–by aligning the National Policy and Strategy on Disaster Risk Management and its strategic program and investment framework with these two global and continental frameworks. The alignment with both accords in Ethiopia was manifested in different initiatives and programs. For instance: in the country’s DRM mainstreaming guideline, disaster risk-informed development planning manuals, and DRM research and training road map, as well as other tools and approaches developed with partners since 2015. Additionally, as part of this endeavor and with the view to implement decentralization/localization of the DRM policy, it was translated into local anguages in addition to Amharic, such as Oromiffa and Somali. Furthermore, as part of the ongoing government reform process, the EDRMC gained autonomy and is now under the PM’s office. This not only showcases the current government’s commitment but also, if implemented, provides leverage in terms of disaster coordination and management at all levels throughout the country. The current reform and evolving changes at national, regional, continental and global levels also gave the organization the opportunity to revise the 2013 DRM policy and strategy that will enforce mainstreaming and decentralization of DRM in all sectoral, regional, zonal and Woreda plans.

Another milestone in 2021 was that, with the financial and technical assistance of Building Resilience in Ethiopia (BRE) and the Ministry of Planning and Development (MPD), DRM actions and strategies were incorporated into the Ten-Year Development Plan (TYDP). EDRMC is currently finalizing the DRM legal framework that will include mandatory legal provisions and associated directives to establish and operationalize the DRM system and establish response thresholds for ownership and accountability. In addition to increased capacity for intervention implementation, the projected changes will necessitate a strong monitoring, evaluation, and learning system that tracks advancements made and outcomes attained through performance indicators. A DRM monitoring and evaluation framework were developed as a result, and the baseline analysis for establishing the measurement targets is currently being completed.

Ethiopia championed priority 1 in several achievements in both rural and urban settings. Through Woreda disaster risk profiling (WDRP), it has collected and profiled risks for 485 woredas and used them to develop disaster risk reduction and contingency plans for over 350 districts. This flagship program profiled and did the same with the breadth of geographically disaggregated and multidimensional data produced at the lowest administrative level possible, to assist risk-informed development planning and achieve a very decentralized early warning system in the country. There have also been accomplishments in the urban setting. The country began profiling urban risks in Addis Ababa in 2015/2016 and has now expanded to Dire Dawa city municipality. Progress has also been made in some sectors, such as the national metrological institute (in charge of providing weather-related information), which has increased its accuracy to 76% in terms of correctly predicting hazards for users and has greatly improved data availability and accessibility.

Despite only working within a few sectors and non-state actors, the country also made significant progress in disaster risk governance. Disaster Risk Governance in Ethiopian DRM policy and policy strategy is well articulated to be decentralized, which has also been well aligned with the constitution model that the country is adopting. The issue of risk governance as a whole requires this. Notwithstanding with owning a well-aligned DRM policy and strategy that provides hazard-specific mandates for line sectors and locating a separate DRM platform at the Federal level, progress was insufficient, given that risk governance must be multi-sectoral, multi-hazard, and multi-disciplinary.

Despite the aforementioned, it doesn’t imply that the country hasn’t advanced in some aspects. The EUDRM decentralization, in which they directly collaborate with regions to implement the DRM strategy, was a component of this risk governance endeavor. The EU-DRM decentralization project is being implemented in five national regional states of the country. Another case in point is the AECID program, which showed significant progress in terms of bringing a model of disaster resilience in Ethiopia to SNNPR.

Despite some increasing efforts, investment in DRR and resilience building in Ethiopia has not progressed very far, as DRR is not sufficiently mainstreamed in policies and investments across all sectors and is not yet fully integrated into the implementation of the 2030 Agenda for Sustainable Development.

In terms of DRM functions, most budgeting and funding continues to be dominated by the response function. This finding is also supported by a recent UNDRR study on risk-sensitive budgeting. Despite the lower level of investment in disaster risk reduction and prevention, the country has made notable progress in lowering natural disaster-related mortality and economic losses. Taking the recent COVID-19 pandemic, drought response in many parts of the country, humanitarian response in Tigray, Amhara, and Afar, and flooding as examples, the country has generally indicated that its disaster preparedness and response have improved significantly during this period.

Partners who have supported EDRMC in making progress on this global agenda, POA and IGAD DRM, include the European Union, USAID, the World Bank Group, UNDRR, and other UN agencies, the CIMA Research Foundation, the Building Resilience in Ethiopia (BRE) project, the Bill and Melinda Gates Foundation, AECID, the Asian Disaster Preparedness Center, EU-DRM decentralization, and all other development partners.

Conflicts, desert locust invasions, climate shocks such as floods and droughts, the impact of COVID-19, reduced financial support, and large national trade deficits leading to high inflation and currency devaluation are key drivers of Ethiopia’s humanitarian needs. These factors limit access to nutritious meals, with 75% of households unable to afford nutritious meals. The auxiliary impacts of the Ukrainian struggle will almost certainly raise the costs of staples and nutrient-dense nourishments, compounding nourishment and nourishment frailty. These challenges and a recent Horn of Africa forecast that drought will worsen due to the fifth consecutive failure of RF and high inflation, as well as other risks, have recently shown signs that they may continue to affect people’s livelihoods and lives unless measures are taken during the SF’s half-implementation period.

 

Source: Government of Ethiopia

Africa Needs High-quality Data to Achieve Transformation: Macroeconomic Experts

Macroeconomic data experts said African countries need high-quality data to achieve structural transformation and inclusive growth, according to the UN Economic Commission for Africa (UNECA).

ECA said in a press release that the experts urged for concerted data coordination and statisticians to collect data to ensure African countries are generating and disseminating high-quality data to achieve structural transformation.

In the margins of the 8th Statistical Commission for Africa taking place from 24-26 October, the experts held a side event meeting hosted by the ECA’s Macroeconomics and Governance Division (MGD) outlining the urgent needs faced by countries to ensure high-quality data supply, it was learned.

According to the press release, the focus of the side-event was underpinned by the growing and urgent need for timely accurate, complete, reliable and relevant data and statistics to inform policy, which remains a significant challenge across Africa.

During the event, Macroeconomic and Governance Division Economic Affairs Officer, Atkeyelsh Persson stressed the need for high-quality data to achieve structural transformation and inclusive growth.

This, she noted, is a key focus of  the Macroeconomic and Governance Division, which aims to serve member states through strengthened and effective development planning, macroeconomic policy analysis, and enhanced public sector financial management and economic governance.

The Macroeconomic and Governance Division faces challenges in the area of data quality and availability, timeliness, completeness, consistency, and accuracy, Persson stated.

According to economic affairs officer, these challenges hinder its support to member states, such as in the area of macroeconomic modeling, development planning, and measuring illicit financial flows (IFF).

For instance, Persson pointed out, incomplete and inconsistent data results in biased estimation in macroeconomic modeling.

“Our aim is to continue to strive for data quality and support countries in order to resolve these challenges.”

Jairo Arrow, Official Statistics Expert, former Deputy Director-General of Statistics in South Africa and Vice President of International Association of Survey Statisticians spoke about modernizing data ecosystems and quality statistics.

He drew from his rich experience in and compared the production of statistics to building a house, in which sampling frames correspond to foundations, surveys and censuses to pillars, national accounts to roof, and policy outcomes to flagpoles for assessment of poverty and inequality, economic growth, unemployment.

“Regular maintenance and constant consultation with users on data adequacies and gaps are required,” he said. He noted that poor quality statistics could lead to disastrous consequences.

Member states shared experiences and lessons learnt, with Rwanda informing the meeting on the country’s advancements in computerization for data collection and big data techniques.

Moreover, the importance of sound methodologies was stressed during the discussion as is the need to improve the national statistics ecosystem and create favorable conditions for improving methodologies in local contexts.

 

Source: Ethiopia News Agency

16th Ethio-Djibouti Joint Ministerial Meeting Kicks Off in Addis Ababa

The 16th Ethio-Djibouti Joint Ministerial Meeting kicked off today in Addis Ababa.

The aim of meeting is to discuss on ways of enhancing the cooperation on regional and multilateral and economic integration between the two countries.

During its three-day deliberations, the Joint Ministerial Meeting is expected to discuss on the political, economic, infrastructure, and logistics cooperation between the two countries.

Legal and justice as well as immigration, border trade agreements, and port related issues, agriculture among other areas are also expected to be the other agenda on the meeting, it was indicated.

At the opening of the meeting, Director General of African Affairs at the Ministry of Foreign Affairs, Ambassador Fissaha Shawel said that the two countries have  strong long-standing and historical and bilateral relationship.

He said this meeting will help to exchange views on the importance of the relations between Ethiopia and Djibouti.

Head of the Djiboutian delegation, Mahdi Obsieh said Ethiopia and Djibouti have intertwined with culture, religion, language, tradition and history.

He elaborated that the two brotherly countries have enjoyed close and multifaceted cooperation which this meeting will create opportunity to elevate  the ties to  a high level.

 

Source: Ethiopia News Agency